Effect of Glucagon-Like Peptide-1 Receptor Agonists and Co-Agonists on Body Composition: Systematic Review and Network Meta-Analysis. Metabolism , vol
Generally, individuals with a body mass index (BMI) of 30 or higher or a BMI of 27 or higher with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol, may qualify for Semaglutide GLP-1 treatment
The medication is doing what its supposed to do without making you miserable
Retatrutide, also known as LY3437943, is a peptide-class triple agonist that activates the GIP, GLP-1, and glucagon receptors, but it is not currently FDA-approved for any indication and is not available as an approved prescription product 1, 2, 3
The absence of specific guidance reflects the lack of robust clinical trial data in this population